Search results for "maintenance"

showing 10 items of 392 documents

Extracellular Vesicles in neural cell interaction and CNS homeostasis

2021

Abstract Central nervous system (CNS) homeostasis critically depends on the interaction between neurons and glia cells. Extracellular vesicles (EVs) recently emerged as versatile messengers in CNS cell communication. EVs are released by neurons and glia in activity‐dependent manner and address multiple target cells within and outside the nervous system. Here, we summarize the recent advances in understanding the physiological roles of EVs in the nervous system and their ability to deliver signals across the CNS barriers. In addition to the disposal of cellular components via EVs and clearance by phagocytic cells, EVs are involved in plasticity‐associated processes, mediate trophic support a…

Nervous systemCancer ResearchCell signalingQH301-705.5PhysiologyCentral nervous systemReviewsReviewexosomesBiologyblood–brain barrierBiochemistry Genetics and Molecular Biology (miscellaneous)NeuroprotectionneuroinflammationmedicineBiology (General)neuron–glia interactionNeural cellNeuroinflammationaxonal maintenancesynaptic plasticityMicrovesiclesmedicine.anatomical_structureSynaptic plasticityMolecular Medicinein vivo imagingNeurosciencemicrovesiclesFASEB BioAdvances
researchProduct

Economie assessments on the use of wired and wireless recharging systems in Italian and European market

2017

The conductive charging method for the electric vehicles is the most widespread, since it is the simplest and has higher returns. In the last years, alternative charging technologies have been investigated. Between these wireless charging systems have been large diffusion and have been commercialized by some manufacturer. Wireless charging systems for electric vehicles have some advantages respect the wired ones, not obliging the user to connect physically the vehicle to the electric charging station. Assuming the efficiency declared by the manufacturer of wireless systems the authors, in this paper, estimate the maximum cost that wireless recharging systems can have to be, however, more fa…

Net Present ValueComputer scienceBiomedical EngineeringEnergy Engineering and Power Technology02 engineering and technologySettore ING-IND/32 - Convertitori Macchine E Azionamenti ElettriciInductive chargingNet present valueMaintenance engineeringCharging stationReduction (complexity)Order (exchange)Economic indexewireless recharging systems0202 electrical engineering electronic engineering information engineeringWireless0501 psychology and cognitive sciencesRenewable Energy050107 human factorsSustainability and the Environmentbusiness.industryRenewable Energy Sustainability and the Environment05 social sciencesrecharging columns020206 networking & telecommunicationsrecharging columnefficiencywireless recharging systemeconomic indexesValue (economics)economic indexes; efficiency; Net Present Value; recharging columns; wireless recharging systems; Energy Engineering and Power Technology; Biomedical Engineering; Renewable Energy Sustainability and the EnvironmentTelecommunicationsbusiness
researchProduct

On Constructing Persistent Identifiers with Persistent Resolution Targets

2016

Persistent Identifiers (PID) are the foundation referencing digital assets in scientific publications, books, and digital repositories. In its realization, PIDs contain metadata and resolving targets in form of URLs that point to data sets located on the network. In contrast to PIDs, the target URLs are typically changing over time; thus, PIDs need continuous maintenance -- an effort that is increasing tremendously with the advancement of e-Science and the advent of the Internet-of-Things (IoT). Nowadays, billions of sensors and data sets are subject of PID assignment. This paper presents a new approach of embedding location independent targets into PIDs that allows the creation of maintena…

Networking and Internet Architecture (cs.NI)FOS: Computer and information scienceslcsh:T58.5-58.64lcsh:Information technologyComputer sciencebusiness.industryOverlay network020206 networking & telecommunications02 engineering and technologycomputer.file_formatMaintenance engineeringlcsh:QA75.5-76.95IdentifierMetadataComputer Science - Networking and Internet ArchitectureData accessEncoding (memory)0202 electrical engineering electronic engineering information engineering020201 artificial intelligence & image processinglcsh:Electronic computers. Computer sciencebusinessDisseminationBitTorrentcomputerComputer network
researchProduct

Optimal maintenance system for offshore wind turbines

2010

In the last years, the industry of wind power generators has developed in many aspects. The offshore plants have some benefits over the onshore ones but their implementation is really expensive.Based in that cost, this paper describes the importance of applying an optimal maintenance based in priorities and cost. It also studies the maintenance types and proposes a scheme of maintenance for offshore plants.

Offshore wind powerWind powerRenewable Energy Sustainability and the Environmentbusiness.industryOptimal maintenanceEnergy Engineering and Power TechnologyEnvironmental scienceSubmarine pipelineElectrical and Electronic EngineeringbusinessMarine engineeringRenewable Energy and Power Quality Journal
researchProduct

Conventional induction and post-remission therapy in APL: have we arrived?

2014

Since the introduction of all-trans-retinoic acid, the use of this molecularly targeted treatment in combination with anthracycline-based chemotherapy has completely changed the prognosis of acute promyelocytic leukemia (APL) turning it into the most curable acute myeloid leukemia. Also, the use of risk-adapted protocols has optimized the drug combination and the most appropriate dose intensity for each subset of patients classified according to both risk of relapse and vulnerability to drug toxicity. Recent developments have included the investigation of the role of arsenic trioxide (ATO) as front-line treatment after its success in relapsed APL, both to minimize or even omit the use of cy…

OncologyAcute promyelocytic leukemiaDrugmedicine.medical_specialtyHarringtoninesAnthracyclinemedia_common.quotation_subjectmedicine.medical_treatmentClinical BiochemistryTretinoinPharmacologyArsenicalsTargeted therapyMaintenance Chemotherapychemistry.chemical_compoundArsenic TrioxideLeukemia Promyelocytic AcuteInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansMulticenter Studies as TopicAnthracyclinesRelapse riskArsenic trioxidemedia_commonChemotherapyClinical Trials as Topicbusiness.industryMercaptopurineDaunorubicinRemission InductionMyeloid leukemiaOxidesmedicine.diseaseConsolidation ChemotherapyMethotrexateOncologychemistryMitoxantronebusinessHomoharringtonineIdarubicinBest practiceresearch. Clinical haematology
researchProduct

Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute …

1993

Aggressive chemotherapy of advanced myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) evolving from MDS, subacute AML and secondary AML has usually been associated with low complete remission (CR) rates, a high incidence of early death, and low disease-free survival. We therefore have initiated a phase-III trial of aggressive chemotherapy consisting of idarubicin, cytosine arabinoside, and VP-16 to improve the CR rate. Each chemotherapy cycle is followed by G-CSF to accelerate neutrophil recovery and to reduce the incidence of infections. Until now, 19 patients with high-risk AML have been entered. The CR rate is 47%, with only one death during induction. Patients achieving CR ar…

OncologyAdultMalemedicine.medical_specialtymedicine.medical_treatmentMaintenance therapyhemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineSecondary Acute Myeloid LeukemiaIdarubicinHumansEtoposideAgedEtoposideChemotherapybusiness.industryRemission InductionCytarabineMyeloid leukemiaHematologyGeneral MedicineMiddle AgedGranulocyte colony-stimulating factorLeukemia Myeloid AcuteMyelodysplastic SyndromesImmunologyCytarabineInterleukin-2FemalebusinessIdarubicinmedicine.drugAnnals of hematology
researchProduct

R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: Final results of FOLL05 trial from the Fondazione Itali…

2012

8006 Background: The optimal chemotherapy regimen for patients with advanced, active follicular lymphoma (FL) has not been established yet. We conducted a randomized trial comparing R-CVP with R-CHOP and R-FM. Methods: Previously untreated patients with advanced FL were randomly assigned to receive 8 doses of rituximab associated to 8 cycles of CVP, or 6 cycles of CHOP or FM (fludarabine 25 mg/m2 day 1-3, mitoxantrone 10 mg/m2 day 1). No maintenance therapy was allowed. The principal study end point was Time to Treatment Failure (TTF). Events in TTF were failure of induction therapy, progressive or relapse disease and death from any causes. In order to show a hazard ratio between each expe…

OncologyCancer ResearchMitoxantronemedicine.medical_specialtybusiness.industryHazard ratioFollicular lymphomaCHOPmedicine.diseaseChemotherapy regimenSurgeryFludarabineOncologyMaintenance therapyInternal medicinemedicineRituximabbusinessmedicine.drug
researchProduct

PARALLEL 303: Phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients (pts) with inoperable locally advanced or metastati…

2021

3109 Background: A subset of gastric cancers exhibits platinum sensitivity and genomic instability that is characteristic of homologous recombination deficiency (HRD). Cells with HRD are sensitive to poly (ADP-ribose) polymerase (PARP) inhibition. PARP inhibitor maintenance therapy following platinum-based chemotherapy has been a successful treatment strategy in pts with ovarian cancer. Pamiparib is an orally administered selective PARP protein 1 and 2 (PARP1/2) inhibitor that has shown potent DNA-PARP trapping activity and crosses the blood brain barrier in preclinical studies. In early phase clinical studies (NCT02361723; NCT03333915), pamiparib showed an acceptable safety profile and pr…

OncologyCancer Researchmedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentFirst lineLocally advancedPlacebolaw.inventionMetastatic gastric cancerOncologyRandomized controlled trialMaintenance therapylawInternal medicinemedicineIn patientbusinessJournal of Clinical Oncology
researchProduct

Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo a…

2019

Background In patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC), the role of maintenance therapy after first-line treatment with chemotherapy plus antiepidermal growth factor receptor (EGFR) monoclonal antibodies (MoAb) is still an object of debate. Methods We assessed the efficacy and safety of regorafenib as a switch maintenance strategy after upfront 5-fluorouracil-based chemotherapy plus an anti- EGFR MoAb in patients with RAS WT mCRC. RAVELLO was a phase III, international, double-blind, placebocontrolled, academic trial. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival and toxicity. Regorafenib or placebo were a…

OncologyCancer Researchmedicine.medical_specialtyColorectal cancerMedicinamedicine.medical_treatmentcolorectal cancerPlaceboacademic researchlcsh:RC254-282chemistry.chemical_compoundMaintenance therapyInternal medicineRegorafenibmedicineClinical endpoint1506Original ResearchChemotherapymaintenance treatmenttreatmentbusiness.industryfundingmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensFirst line treatmentOncologychemistryToxicityregorafenibbusinessRAS WT
researchProduct

Phase II study of pemetrexed (Pem) and cisplatin (Cis) plus cetuximab (Cet) followed by Pem and Cet maintenance therapy in patients (Pts) with advanc…

2012

7554 Background: A prospective, nonrandomized, multicenter study was conducted to assess the effect of adding cet to pem and cis in pts with advanced nonsquamous NSCLC. Methods: 113 Caucasian performance status 0-1 pts received 1st line pem (500 mg/m2) and cis (75 mg/m2) on day 1 (21d cycle) for 4-6 cycles and cet (400 mg/m2 loading dose followed by 250 mg/m2) weekly. Non-progressive pts received pem 500 mg/m2 on day 1 (21d cycle) plus cet (250mg/m2 weekly) until progression. Pts received vitamin B12/folic acid and dexamethasone. Primary endpoint was objective response rate (ORR) (RECIST 1.0). Secondary endpoints were progression free survival (PFS), 1 year survival rate, translational res…

OncologyCisplatinCancer Researchmedicine.medical_specialtyCetuximabbusiness.industryPhases of clinical researchnon-small cell lung cancer (NSCLC)medicine.diseasePemetrexedOncologyMaintenance therapyMulticenter studyInternal medicinemedicineIn patientbusinessmedicine.drugJournal of Clinical Oncology
researchProduct